Tags : MOVe-OUT Trial

Merck and Ridgeback Report Interim Results of Molnupiravir in P-III

Tuba Khan October 1, 2021

Shots: The P-III MOVe-OUT trial evaluates molnupiravir vs PBO in 1550 non-hospitalized adult patients with COVID-19 with at least one risk factor associated with poor disease outcomes & symptom onset […]readmore

Tags : MOVe-OUT Trial

Merck and Ridgeback Report Interim Results of Molnupiravir in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : MOVe-OUT Trial

Merck and Ridgeback Report Interim Results of Molnupiravir in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company